9.2 Protocol Review and Monitoring System (PRMS) The Protocol Review and Monitoring System at the Arizona Cancer Center facilitates the our Scientific Review Committee (SRC), which is staffed with appropriate faculty and scientific representation in all disiciplines, to include but not be limited to medical hematology/oncology, surgical oncology, gynecologic oncology, radiafion oncology, pediatric hematology/oncology. Other medical subspecialities, cancer chemoprevention, and, translationals studies with clinical and basic science collaborators are also covered. The primary responsibilities of the AZCC SRC include the following: ? Review of all new hypothesis-generated interventional protocols of diagnostic or therapeutic nature as well as longitudinal population-based studies involving patients, patient samples, or patient records conducted by AZCC members to ensure the highest scientific quality of clinical research in advance of IRB submission. ? Review ongoing progress of protocols conducted by AZCC members to maximize scientific validity, assure timely and effective performance. - ? Evaluate the merit of eligible protocols for utilization of AZCC shared resources/services based upon objective scientific review. ? Promote unified standards for protocol implementation and translational research among AZCC investigators of various disciplines involved in cancer treatment and care. Regardless of the protocol type, no clinical research study eligible for SRC review can be submitted to the institutional IRB until SRC approval is granted. SRC actions and approval will accompany IRB submissions. In exceptional circumstances, concurrent IRB review may be allowed with written permission from the SRC Chairman.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arizona
United States
Zip Code
Casillas, Andrea L; Toth, Rachel K; Sainz, Alva G et al. (2018) Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 24:169-180
Nair, Uma S; Bell, Melanie L; Yuan, Nicole P et al. (2018) Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. Public Health Rep 133:200-206
Smithey, Megan J; Venturi, Vanessa; Davenport, Miles P et al. (2018) Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection. Proc Natl Acad Sci U S A 115:E6817-E6825
Maisel, Sabrina; Broka, Derrick; Schroeder, Joyce (2018) Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. Oncotarget 9:6463-6477
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Augustus, Gaius J; Ellis, Nathan A (2018) Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. Am J Pathol 188:291-303
Das, Lipsa; Gard, Jaime M C; Prekeris, Rytis et al. (2018) Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer. Mol Cancer Res 16:1319-1331
Cox, Christopher M; Lu, Ruifeng; Salcin, Kaan et al. (2018) The Endosomal Protein Endotubin Is Required for Enterocyte Differentiation. Cell Mol Gastroenterol Hepatol 5:145-156
?aniewski, Pawe?; Barnes, Dominique; Goulder, Alison et al. (2018) Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Sci Rep 8:7593
Demark-Wahnefried, Wendy; Schmitz, Kathryn H; Alfano, Catherine M et al. (2018) Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68:64-89

Showing the most recent 10 out of 1336 publications